Walden’s clinical-stage program is a humanized monoclonal antibody that inhibits suPAR, a cause of podocyte dysfunction and kidney disease, which is being evaluated in a Phase 2 Basket study.

The new drug is thought to have a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production, and promoting podocyte stability in the ...

In this study, we investigated the mechanism by which the SGLT2 inhibitor canagliflozin attenuates podocyte injury by reversing the imbalance in Helper T cell 1 (Th1)/Helper T cell 2 (Th2) in ...

An SGLT2 knockout monoclonal podocyte cell line was generated using the CRISPR/Cas9 system to examine the cellular and molecular mechanisms. Conclusion This study confirmed the renoprotective effect ...

Introduction: Renal podocyte injury, apoptosis and autophagy are involved in the occurrence and development of diabetic nephropathy (DN). Kaempferol (KPF) has the promotion of autophagy and inhibition ...

Here, we argue that the classic definitions of preeclampsia, based on concepts that are now more than 50 years old, have become outdated and that the definition could be modernized to take account of ...

aCenter for Renal Translational Medicine/Institute for Metabolomic Medicine, University of California San Diego, San Diego, CA, United States bDepartment of Clinical and Molecular Medicine, Faculty of ...